MPO and anti-neutrophil cytoplasmic antibody-associated vasculitis: This was relatively lower than previous studies, in which AAV development was seen in 27.78% of MPO-ANCA–positive IPF patients [13] and 34.62% of MPO-ANCA–positive IIPs patients [19].